Adverse events following immunization with vaccines containing adjuvants

Immunologic Research

Volumn 56, Issue 2-3, 2013, Pages 299-303

  Cerpa Cruz, S ^a   Paredes Casillas, P ^a   Landeros Navarro, E ^a   Bernard Medina, A G ^a   Martinez Bonilla G ^a   Gutierrez Urena S ^a  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

Adjuvant; Aluminum; Autoimmunity; Syndrome; Thiomersal; Vaccines

Indexed keywords

2 PHENOXYETHANOL; ALBUMIN; ALUMINUM SALT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FORMALDEHYDE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MAGNESIUM CHLORIDE; NEOMYCIN; PHENOL; POTASSIUM CHLORIDE; SORBITOL; SQUALENE; THIOMERSAL; VACCINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ADULT ONSET STILL DISEASE; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; FEVER; GUILLAIN BARRE SYNDROME; HOSPITALIZATION; HUMAN; IMMUNIZATION; MALE; MUSCLE WEAKNESS; MYALGIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; VACCINATION REACTION;

ABNORMALITIES, MULTIPLE; ADJUVANTS, PHARMACEUTIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRALGIA; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FEVER; FOLLOW-UP STUDIES; GUILLAIN-BARRE SYNDROME; HUMANS; INCIDENCE; INFANT; MALE; MEXICO; MIDDLE AGED; PREVALENCE; RISK FACTORS; SKIN DISEASES; SYNDROME; VACCINATION; VACCINES; YOUNG ADULT;

EID: 84879553428     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8400-4     Document Type: Article

References (28)

1. Nakayama T. Influenza vaccine and adjuvant. Yakugaku Zasshi. 2011;131(12):1723-31.
2. Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines. 2007;6(5):673-84. (Pubitemid 47607845)
3. Cruz-Tapias P, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389-93.
4. de Veer M, Meeusen E. New developments in vaccine research - unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195-204.
5. Leitner WW. Vaccine adjuvants: is the pipeline clogged? Immunotherapy. 2012;4(6):565-7.
6. Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):539-50.
7. Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4-8.
8. WHO. Surveillance of adverse events following immunization. Field guide for managers of immunization programmes. Geneva. 1997.
9. WHO. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization. Geneva. 2000.
10. Vitoriano-Souza J, et al. Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid A. PLoS One. 2012;7(7):e40745.
11. Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. Vaccine. 2012.
12. Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012;21:210-6.
13. Lerner A. Aluminum as an adjuvant in Crohn's disease induction. Lupus. 2012;21(2):231-8.
14. Zafrir Y, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146-52.
15. Perdan-Pirkmajer K, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus. 2012;21(2):175-83.
16. Ray P, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. Vaccine. 2011;29(38):6592-7.
17. Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012;21(2):223-30.
18. Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005;99(9):1895-8. (Pubitemid 41253779)
19. Eisenbarth SC, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122-6. (Pubitemid 351871731)
20. Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21(2):184-9.
21. Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus. 2012;21(2):118-20.
22. Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31(3):103-9.
23. Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21(2):217-22.
24. Lerner A. Aluminum as an adjuvant in Crohn's disease induction. Lupus. 2012;21(2):231-8.
25. Barile JP, et al. Thimerosal exposure in early life and neuropsychological outcomes 7-10 years later. J Pediatr Psychol. 2012;37(1):106-18.
26. Madi A. Being on the track of thimerosal. Review. Acta Microbiol Immunol Hung. 2005;52(1):95-103. (Pubitemid 40694688)
27. Barregard L, et al. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine. Toxicol Sci. 2011;120(2):499-506.
28. Soriano A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21(2):153-7.